Cargando…

Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), infects one third of the world's population. Among these infections, clinical isolates belonging to the W-Beijing appear to be emerging, representing about 50% of Mtb isolates in East Asia, and about 13% of all Mtb isol...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopal, Radha, Monin, Leticia, Slight, Samantha, Uche, Uzodinma, Blanchard, Emmeline, A. Fallert Junecko, Beth, Ramos-Payan, Rosalio, Stallings, Christina L., Reinhart, Todd A., Kolls, Jay K., Kaushal, Deepak, Nagarajan, Uma, Rangel-Moreno, Javier, Khader, Shabaana A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022785/
https://www.ncbi.nlm.nih.gov/pubmed/24831696
http://dx.doi.org/10.1371/journal.ppat.1004099
_version_ 1782316468196605952
author Gopal, Radha
Monin, Leticia
Slight, Samantha
Uche, Uzodinma
Blanchard, Emmeline
A. Fallert Junecko, Beth
Ramos-Payan, Rosalio
Stallings, Christina L.
Reinhart, Todd A.
Kolls, Jay K.
Kaushal, Deepak
Nagarajan, Uma
Rangel-Moreno, Javier
Khader, Shabaana A.
author_facet Gopal, Radha
Monin, Leticia
Slight, Samantha
Uche, Uzodinma
Blanchard, Emmeline
A. Fallert Junecko, Beth
Ramos-Payan, Rosalio
Stallings, Christina L.
Reinhart, Todd A.
Kolls, Jay K.
Kaushal, Deepak
Nagarajan, Uma
Rangel-Moreno, Javier
Khader, Shabaana A.
author_sort Gopal, Radha
collection PubMed
description Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), infects one third of the world's population. Among these infections, clinical isolates belonging to the W-Beijing appear to be emerging, representing about 50% of Mtb isolates in East Asia, and about 13% of all Mtb isolates worldwide. In animal models, infection with W-Beijing strain, Mtb HN878, is considered “hypervirulent” as it results in increased mortality and causes exacerbated immunopathology in infected animals. We had previously shown the Interleukin (IL) -17 pathway is dispensable for primary immunity against infection with the lab adapted Mtb H37Rv strain. However, it is not known whether IL-17 has any role to play in protective immunity against infection with clinical Mtb isolates. We report here that lab adapted Mtb strains, such as H37Rv, or less virulent Mtb clinical isolates, such as Mtb CDC1551, do not require IL-17 for protective immunity against infection while infection with Mtb HN878 requires IL-17 for early protective immunity. Unexpectedly, Mtb HN878 induces robust production of IL-1β through a TLR-2-dependent mechanism, which supports potent IL-17 responses. We also show that the role for IL-17 in mediating protective immunity against Mtb HN878 is through IL-17 Receptor signaling in non-hematopoietic cells, mediating the induction of the chemokine, CXCL-13, which is required for localization of T cells within lung lymphoid follicles. Correct T cell localization within lymphoid follicles in the lung is required for maximal macrophage activation and Mtb control. Since IL-17 has a critical role in vaccine-induced immunity against TB, our results have far reaching implications for the design of vaccines and therapies to prevent and treat emerging Mtb strains. In addition, our data changes the existing paradigm that IL-17 is dispensable for primary immunity against Mtb infection, and instead suggests a differential role for IL-17 in early protective immunity against emerging Mtb strains.
format Online
Article
Text
id pubmed-4022785
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40227852014-05-21 Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection Gopal, Radha Monin, Leticia Slight, Samantha Uche, Uzodinma Blanchard, Emmeline A. Fallert Junecko, Beth Ramos-Payan, Rosalio Stallings, Christina L. Reinhart, Todd A. Kolls, Jay K. Kaushal, Deepak Nagarajan, Uma Rangel-Moreno, Javier Khader, Shabaana A. PLoS Pathog Research Article Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), infects one third of the world's population. Among these infections, clinical isolates belonging to the W-Beijing appear to be emerging, representing about 50% of Mtb isolates in East Asia, and about 13% of all Mtb isolates worldwide. In animal models, infection with W-Beijing strain, Mtb HN878, is considered “hypervirulent” as it results in increased mortality and causes exacerbated immunopathology in infected animals. We had previously shown the Interleukin (IL) -17 pathway is dispensable for primary immunity against infection with the lab adapted Mtb H37Rv strain. However, it is not known whether IL-17 has any role to play in protective immunity against infection with clinical Mtb isolates. We report here that lab adapted Mtb strains, such as H37Rv, or less virulent Mtb clinical isolates, such as Mtb CDC1551, do not require IL-17 for protective immunity against infection while infection with Mtb HN878 requires IL-17 for early protective immunity. Unexpectedly, Mtb HN878 induces robust production of IL-1β through a TLR-2-dependent mechanism, which supports potent IL-17 responses. We also show that the role for IL-17 in mediating protective immunity against Mtb HN878 is through IL-17 Receptor signaling in non-hematopoietic cells, mediating the induction of the chemokine, CXCL-13, which is required for localization of T cells within lung lymphoid follicles. Correct T cell localization within lymphoid follicles in the lung is required for maximal macrophage activation and Mtb control. Since IL-17 has a critical role in vaccine-induced immunity against TB, our results have far reaching implications for the design of vaccines and therapies to prevent and treat emerging Mtb strains. In addition, our data changes the existing paradigm that IL-17 is dispensable for primary immunity against Mtb infection, and instead suggests a differential role for IL-17 in early protective immunity against emerging Mtb strains. Public Library of Science 2014-05-15 /pmc/articles/PMC4022785/ /pubmed/24831696 http://dx.doi.org/10.1371/journal.ppat.1004099 Text en © 2014 Gopal et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gopal, Radha
Monin, Leticia
Slight, Samantha
Uche, Uzodinma
Blanchard, Emmeline
A. Fallert Junecko, Beth
Ramos-Payan, Rosalio
Stallings, Christina L.
Reinhart, Todd A.
Kolls, Jay K.
Kaushal, Deepak
Nagarajan, Uma
Rangel-Moreno, Javier
Khader, Shabaana A.
Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection
title Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection
title_full Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection
title_fullStr Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection
title_full_unstemmed Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection
title_short Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection
title_sort unexpected role for il-17 in protective immunity against hypervirulent mycobacterium tuberculosis hn878 infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022785/
https://www.ncbi.nlm.nih.gov/pubmed/24831696
http://dx.doi.org/10.1371/journal.ppat.1004099
work_keys_str_mv AT gopalradha unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT moninleticia unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT slightsamantha unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT ucheuzodinma unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT blanchardemmeline unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT afallertjuneckobeth unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT ramospayanrosalio unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT stallingschristinal unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT reinharttodda unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT kollsjayk unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT kaushaldeepak unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT nagarajanuma unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT rangelmorenojavier unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection
AT khadershabaanaa unexpectedroleforil17inprotectiveimmunityagainsthypervirulentmycobacteriumtuberculosishn878infection